Agenus | AGEN - Cost Of Sales


Agenus reported $642K in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Agenus USD 642K 399K Sep/2025
Amgen USD 1.6B 187M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Celldex Therapeutics USD 54.2M 8.94M Jun/2025
CSL USD 3.87B 2.08B Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Glaxosmithkline GBP 1.88B 1.6B Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
Intrexon USD 1.01M 344K Jun/2024
J&J USD 8B 67M Jun/2026
Jiangsu Hengrui CNY 1.09B 76.27M Mar/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
MacroGenics USD 9.53M 585K Mar/2026
Merck EUR 2.07B 219M Mar/2026
Merck USD 2.94B 380M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Novavax USD 22.1M 608K Dec/2025
Pfizer USD 4.59B 1.7B Mar/2026
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Veracyte USD 38.49M 794K Mar/2026